Laxmi joined mAbxience in May´2019, as Chief Scientific Officer to head the biosimilar research and Development in Mabxience and as member of Executive Team.
Laxmi is a competent professional with over 20 years of experience in field of biologics and complex molecule, which includes, fermentation-based statin, insulins, biosimilar Mabs, novel molecules including oral insulin and bi-specific antibodies. Her core competency is analytical, CMC development and R&D strategy.
Laxmi held senior leadership positions and has proven record of leading teams to collaborate and succeed. Prior to joining Mabxience Laxmi was head of CMC and Project management in Alvotech Iceland for a year and half. Previous experiences include long stint of 15 year in Biocon Limited where she held executive positions of increasing responsibility such as senior leadership position in analytical research and development to heading large team of complex analytics. Before joining Biocon Laxmi had a two-year early experience in research in AstraZeneca India.
During her Biocon experience, Laxmi was the global project lead for Biocon-Mylan collaborative program for the First biosimilar Peg filgrastim approval by FDA and EMA. Laxmi has also lead CMC and analytics for other biosimilar antibodies and insulin analogs towards global submission and approval. This includes first Trastuzumab biosimilar approval by FDA, associated ADCOM and PAI.
Laxmi is trained chemist switched to biologic and analytical sciences. She has PhD degree in Synthetic Organic Chemistry from Banaras Hindu University, India, with post-doctoral experience in IISc and other CSIR laboratories. Laxmi has more than 25 publication and 8 active patents to her credit.